P-ISSN 2587-2400 | E-ISSN 2587-196X
Ejmo Kapak
EJMO Volume : 7 Issue : 1 Year : 2023
EJMO. 2020; 4(2): 137-138 | DOI: 10.14744/ejmo.2020.87844

ACE 2 in the Context of COVID 19 – An Opportunity for us or the Virus

Oliyath Ali1, Ishrit Yasin2
1Department of ENT & HNS, District Hospital Kargil, Ladakh, India, 2Department of Dental Surgery, District Hospital Kargil, Ladakh, India,

ACE 2 acts a receptor for Spike S1 protein of SARS CoV 2. It has a protective role in acute lung injury and ARDS. Being a rate limiting factor in the pathogenesis of COVID 19 it can offers multiple avenues for therapeutic measures. The soluble form of ACE 2 if we can give in an inhaler or nebulised form can act as a competitive agent for viral binding in the lungs thus somewhat sparing the trans membrane ACE 2 from viral attack. An antibody directed against the ACE 2 receptor can have the same effect. As the human corona virus NL63 also binds to ACE 2 receptor in the same region as SARS CoV. Therefore co-infection with NL63 can be a disease modifier as NL63 causes mild disease in most of the cases. Also a potent selective inhibitor of ACE 2 can also be tested as a therapeutic option.

Cite This Article

Ali O, Yasin I. ACE 2 in the Context of COVID 19 – An Opportunity for us or the Virus. EJMO. 2020; 4(2): 137-138

Corresponding Author: Oliyath Ali

Full Text PDF PDF Download